Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study

This study is testing a new chemotherapy regimen — a fractionated (split-dose) version of liposomal irinotecan (a specially packaged form of a chemo drug) combined with 5-FU/leucovorin and bevacizumab — as a second-line treatment for advanced colorectal cancer that progressed after oxaliplatin-based first-line therapy. **You may be eligible if...** - You are 18 or older with confirmed advanced colorectal cancer - Your cancer progressed during or within 6 months of first-line oxaliplatin-based chemotherapy, or within 1 year after completing adjuvant oxaliplatin treatment - Your general health score (ECOG) is 0 or 1 - You have measurable disease on scans - Your blood counts, kidney, and liver function are adequate **You may NOT be eligible if...** - You have another active cancer history (except fully treated basal cell or cervical in situ) - You have uncontrolled high blood pressure or recent heart attack/heart failure - You have active brain metastases - You have had recent bowel perforation, fistula, or abdominal surgery complications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.